Advertisement
AME vs EMR
Which Stock Would AI Choose? AMETEK, Inc. (AME) vs. Emerson Electric Co. (EMR) Stock Comparison
Key Takeaways
- AME (AMETEK) is accelerating order growth across defense, aerospace, power, and semiconductor markets, posting record orders and backlog in recent quarters.
- EMR (Emerson Electric) is a global automation and software leader benefiting from secular demand in power, semiconductor, and test-and-measurement verticals.
- Both companies have raised full-year guidance, but AMETEK's organic order growth of roughly 22% recently outpaced Emerson's underlying order growth in the mid-single to high-single digits.
- Emerson carries a larger market capitalization, a growing recurring software revenue base, and a broad analyst "Buy" consensus.
- AMETEK trades at a premium valuation multiple, while Emerson offers comparatively higher dividend yield and greater scale.
Introduction
Investors comparing industrial technology leaders frequently weigh AME and EMR as two high-quality, diversified manufacturers with strong cash generation and acquisition-driven growth. While both operate in adjacent industrial and automation markets, their business models, growth drivers, and risk profiles differ meaningfully. This stock comparison is relevant for traders and long-term investors seeking to understand relative performance, market positioning, and how momentum, valuation, and sector exposure diverge between a niche-focused instruments and electromechanical specialist (AMETEK) and a scaled automation-and-software platform (Emerson). The analysis that follows reviews recent performance, key catalysts, and observable trend signals.
AME Overview and Recent Performance
AME, or AMETEK, Inc., manufactures electronic instruments and electromechanical devices across two operating groups: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). Its diversified portfolio serves niche, mission-critical markets including aerospace and defense, power, semiconductor, and process instrumentation. In recent market activity, AMETEK reported record quarterly results, with sales up roughly 11% year over year and earnings per share (EPS) exceeding consensus estimates. Notably, organic orders accelerated sharply, rising about 22%, supported by broad-based strength in defense, space, missile defense, and unmanned aerial vehicle (UAV) programs. Management raised its full-year EPS outlook to a range of approximately $7.94 to $8.14, citing a record backlog and strong margin expansion. This order momentum has supported positive relative performance, though the stock's premium valuation and a degree of acquisition-dependent growth remain key considerations for investors.
EMR Overview and Recent Performance
EMR, or Emerson Electric Co., is a global automation leader providing software, control systems, measurement instrumentation, valves, and analytical devices. In recent quarters, Emerson delivered rising adjusted EPS and revenue growth driven by its Software & Systems segment and "growth verticals" such as power, semiconductor, and test and measurement. Semiconductor-related orders and power-generation orders grew strongly, and annual contract value for its software portfolio expanded at a high-single-digit pace, adding recurring revenue. Emerson raised its fiscal-year outlook for sales, earnings, and free cash flow, supported by a backlog of roughly $8.2 billion and a robust project funnel. Market sentiment has leaned positive, with a broad consensus "Buy" rating and analyst price targets above recent trading levels, reflecting confidence in automation demand and improving margins.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and sets of securities. Because not every bot suits every market regime, Tickeron curates only the most relevant performers into its Trending AI Robots section. This list is updated to reflect bots that are best aligned with current market conditions, allowing users to review bots with verifiable track records rather than sifting through the full catalog. If you are evaluating an AME versus EMR comparison, exploring the Trending AI Robots page can help you identify automated strategies currently demonstrating relative strength in these names.
Head-to-Head Comparison
Although both companies serve industrial end markets, their market positioning differs. AME operates a highly diversified, acquisition-driven model focused on niche, high-margin instrumentation and electromechanical components, with recent catalysts tied to defense modernization and semiconductor demand. EMR is a larger, more concentrated automation-and-software platform with meaningful recurring revenue and exposure to long-cycle power, liquefied natural gas (LNG), and process-automation projects.
On momentum, AMETEK's recent organic order acceleration stands out, while Emerson's growth is steadier and increasingly software-led. On valuation, AMETEK trades at a higher price-to-earnings multiple, reflecting its quality and growth premium, whereas Emerson offers a comparatively higher dividend yield and broader scale. Key risk factors also diverge: AMETEK's reliance on M&A (mergers and acquisitions) and premium valuation, and Emerson's exposure to softer European and Chinese markets. Sector exposure similarly differs, with AMETEK more levered to defense and aerospace and Emerson more levered to process industries and energy infrastructure.
Tickeron AI Verdict
Based on observable trend consistency, relative positioning, and catalyst breadth, Tickeron's AI would likely lean toward EMR in the current environment. Emerson's combination of a broad analyst "Buy" consensus, expanding recurring software revenue, a sizable backlog, and resilient power and semiconductor demand suggests more durable, diversified momentum. That said, AME's exceptional organic order acceleration and margin expansion indicate stronger near-term growth momentum and remain compelling. In probabilistic terms, an AI system weighing trend stability, breadth of growth drivers, and market sentiment would assign a modest edge to Emerson, while recognizing AMETEK's faster current order trajectory as a meaningful offsetting factor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AME is a Buy and EMR is a StrongBuy.
AME in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 22, 2026
AME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 20 of 37 cases where AME's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for AME crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where AME advanced for three days, in 163 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 123 of 288 cases where AME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 64 cases where AME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 47%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AME as a result. In 37 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 42%.
The Moving Average Convergence Divergence Histogram (MACD) for AME turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 21 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.
AME moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. AME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.096) is normal, around the industry mean (4.327). P/E Ratio (36.484) is within average values for comparable stocks, (38.298). Projected Growth (PEG Ratio) (2.859) is also within normal values, averaging (1.879). Dividend Yield (0.005) settles around the average of (0.032) among similar stocks. P/S Ratio (6.803) is also within normal values, averaging (186.943).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
EMR in upward trend: price rose above 50-day moving average on September 21, 2026
EMR moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on EMR as a result. In 56 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +1.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 213 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 156 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 60 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 25 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.465) is normal, around the industry mean (4.327). P/E Ratio (35.536) is within average values for comparable stocks, (38.298). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.014) settles around the average of (0.032) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
AME | EMR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 13 | 22 | |
SMR RATING 1..100 | 58 | 62 | |
PRICE GROWTH RATING 1..100 | 27 | 19 | |
P/E GROWTH RATING 1..100 | 20 | 34 | |
SEASONALITY SCORE 1..100 | 90 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EMR's Valuation (80) in the Electrical Products industry is in the same range as AME (85) in the Miscellaneous Manufacturing industry. This means that EMR’s stock grew similarly to AME’s over the last 12 months.
AME's Profit vs Risk Rating (13) in the Miscellaneous Manufacturing industry is in the same range as EMR (22) in the Electrical Products industry. This means that AME’s stock grew similarly to EMR’s over the last 12 months.
AME's SMR Rating (58) in the Miscellaneous Manufacturing industry is in the same range as EMR (62) in the Electrical Products industry. This means that AME’s stock grew similarly to EMR’s over the last 12 months.
EMR's Price Growth Rating (19) in the Electrical Products industry is in the same range as AME (27) in the Miscellaneous Manufacturing industry. This means that EMR’s stock grew similarly to AME’s over the last 12 months.
AME's P/E Growth Rating (20) in the Miscellaneous Manufacturing industry is in the same range as EMR (34) in the Electrical Products industry. This means that AME’s stock grew similarly to EMR’s over the last 12 months.
| AME | EMR | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 47% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 42% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 45% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 44% | 1 day ago 59% |
| TrendMonth ODDS (%) | 1 day ago 45% | 1 day ago 56% |
| Advances ODDS (%) | 2 days ago 50% | 10 days ago 62% |
| Declines ODDS (%) | 4 days ago 45% | 3 days ago 56% |
| BollingerBands ODDS (%) | 1 day ago 54% | N/A |
| Aroon ODDS (%) | 1 day ago 43% | 1 day ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AME’s FA Score shows that 3 FA rating(s) are green while EMR’s FA Score has 2 green FA rating(s).
- AME’s FA Score: 3 green, 2 red.
- EMR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AME’s TA Score shows that 5 TA indicator(s) are bullish while EMR’s TA Score has 5 bullish TA indicator(s).
- AME’s TA Score: 5 bullish, 4 bearish.
- EMR’s TA Score: 5 bullish, 3 bearish.
Price Growth
AME (@Industrial Machinery) experienced а +1.40% price change this week, while EMR (@Industrial Machinery) price change was +1.26% for the same time period.
The average weekly price growth across all stocks in the @Industrial Machinery industry was -7.37%. For the same industry, the average monthly price growth was -16.92%, and the average quarterly price growth was -22.09%.
Reported Earning Dates
AME is expected to report earnings on Nov 03, 2026.
EMR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Industrial Machinery (-7.37% weekly)The industry makes and maintains machines for consumers, the industry, and most other companies. While it has traditionally been categorized as heavy industry, some smaller companies are also branching into the light category. The industry is pivotal in providing the equipment for production in businesses like agriculture, mining, industry and construction, gas, electricity and water utilities. It also supplies supporting equipment for almost all sectors of the economy, such as equipment for heating, and air conditioning of buildings. Illinois Tool Works Inc., Parker-Hannifin Corporation and Rockwell Automation Inc are some of the major U.S. companies operating in this industry.
Advertisement
AME and
Correlation & Price change
A.I.dvisor indicates that over the last year, AME has been closely correlated with ROP. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if AME jumps, then ROP could also see price increases.
EMR and
Correlation & Price change
A.I.dvisor indicates that over the last year, EMR has been closely correlated with AME. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if EMR jumps, then AME could also see price increases.